Serum interleukin 38 (IL-38) as a new potential biomarker of pediatric asthma

Abstract

BackgroundBronchial asthma is considered the most prevalent chronic respiratory disease worldwide and is one of the main causes of hospitalization in the pediatric population. Serum interleukin 38 (IL-38) levels are elevated in several inflammatory and autoimmune diseases. However, its exact role in the pathogenesis of these diseases is unclear.ObjectivesTo investigate the role of IL-38 as a potential biomarker in pediatric patients with bronchial asthma.MethodsSerum IL-38 levels were measured in 73 pediatric patients with bronchial asthma (34 atopic and 39 non-atopic) and 30 age- and sex-matched healthy control subjects using enzyme-linked immunosorbent assay.ResultsSerum IL-38 levels were significantly higher in patients with bronchial asthma compared to the control group (p < 0.001). A significant negative correlation was found between serum IL-38 levels and both relative and absolute eosinophilic counts in the atopic group (R = −0.575, p < 0.001 and R = −0.474, p = 0.005, respectively).ConclusionIL-38 could be a useful prognostic and therapeutic biomarker of atopic asthma in pediatric patients.